Predictors of weight loss in adults with topiramate-treated epilepsy. - Wikidata - awgldk - TriplyDB

Predictors of weight loss in adults with topiramate-treated epilepsy.

Predictors of weight loss in adults with topiramate-treated epilepsy.

http://www.wikidata.org/entity/Q44400054

about

Add-on topiramate reduces weight in overweight patients with affective disorders: a clinical case series Efficacy of adjunctive treatments added to olanzapine or clozapine for weight control in patients with schizophrenia: a systematic review and meta-analysis Topiramate-induced modulation of hepatic molecular mechanisms: an aspect for its anti-insulin resistant effect Obesity: Current and potential pharmacotherapeutics and targets.Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice.Topiramate improves neurovascular function, epidermal nerve fiber morphology, and metabolism in patients with type 2 diabetes mellitus.Managing overweight and obesity in adults to reduce cardiovascular disease risk.Predictors of weight loss and maintenance in patients treated with antiobesity drugs Quality of life and objective measures of diabetic neuropathy in a prospective placebo-controlled trial of ruboxistaurin and topiramate.Baseline anandamide levels and body weight impact the weight loss effect of CB1 receptor antagonism in male rats.Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP)Topiramate, pseudotumor cerebri, weight-loss and glaucoma: an ophthalmologic perspective.Topiramate for binge-eating disorder associated with obesity.Phentermine and topiramate for the management of obesity: a review.Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity.Management of epilepsy in the elderly.Topiramate in the treatment of partial and generalized epilepsy.Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate.Management of obesity and cardiometabolic risk - role of phentermine/extended release topiramate.Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.Clinical psychopharmacology of eating disorders: a research update.Phentermine/topiramate for the treatment of obesity.The long-term safety of antiepileptic drugs.Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia.Weight change, genetics and antiepileptic drugs.Combination phentermine/topiramate for obesity treatment in primary care: a review.Pharmacological management of obesity in pediatric patients.Antiepileptic drugs influences on body weight in people with epilepsy.Topiramate effects lipolysis in 3T3-L1 adipocytes.Effects of topiramate use on body composition and resting metabolic rate in migraine patients.Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine.Meralgia paresthetica in the pediatric population: a propos of 2 cases.Atherosclerotic effects of long-term old and new antiepileptic drugs monotherapy: a cross-sectional comparative study.The investigation of the effects of topiramate on the hypothalamic levels of fat mass/obesity-associated protein and neuropeptide Y in obese female rats.Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial.Weight regain after discontinuation of topiramate treatment in patients with migraine: a prospective observational study.Disease Specific Aspects of Malnutrition in Neurogeriatric Patients.Centrally Acting Agents for Obesity: Past, Present, and Future

P2860

Q24793223-A59D312F-D6A3-48D7-A8A7-F63662D840DA Q27691321-3540F3B1-9ACE-4ED9-98D8-F1E00DE4B25E Q28483904-B596A255-2003-4149-A067-4D44EF92C36D Q30243992-C8D50AE3-4615-44E0-8919-F4C2229D513E Q30400748-55753D51-671E-4EEE-A805-C07CBE86ABC2 Q33855470-D00A632D-D649-4FAA-B879-79317E27DC15 Q34106367-3256E0EC-33F5-4229-B680-C385AAA1C180 Q35115097-2224BC9D-D48A-4A7A-A66C-9036E8730B80 Q35337675-987E2836-1D6C-40AB-8222-9E11B3AADF29 Q35442310-65AA0211-1862-4683-B2D2-E986AB44A4E1 Q35724113-D7D6BB6B-153E-48D7-BAB7-0B7E71CBD4E2 Q36414182-7C175B04-6132-43AB-B98F-BEBD176D16EA Q36626311-7CD994DB-9E2D-4B34-A151-81B83B25AFA9 Q36758207-41768979-87FD-48BD-82F7-8067F3FF8751 Q36766224-318A7516-EA8C-4D1F-8BD2-83282AF0673A Q37129785-EA929D0E-E59B-4F31-812F-56EAC82B8A90 Q37129817-D2FE74FE-9FB3-44C6-A876-9A9EB8C942BA Q37164665-ACA1F517-8E4E-4C9D-A01C-81037A464B2C Q37589010-129D77A6-DE65-4D7C-A4CE-88B6C954B0DC Q37779809-AD510CC3-1E75-4038-A1FB-BA0A512459BB Q37857919-B958F00F-1744-445D-85D4-66DA1639BFDF Q38088626-7C52260B-F73B-4777-8B81-A99094CFE95D Q38106856-72C3A63F-BA60-4C9E-BF0C-1AD5AD0786C8 Q38119865-AA459A85-6EA1-431A-A234-A94E7AAA62B2 Q38168942-82B10663-C9BA-4117-A27D-72519ED30524 Q38200830-DA5CD1C8-2152-4229-8271-8A288FA02BA6 Q38264661-67E86A83-6CDD-4E08-86D2-060E85E33C4F Q38285318-DF2B7163-C761-4D60-85BD-563865A322AF Q42817480-4C02BC6C-4990-492D-A03E-70AB2DFF25B8 Q44326104-7419E580-4DD6-4B86-9BD4-68B0651A59F1 Q45176965-6B6B32A5-FBDD-4836-8BF9-51A65190D25A Q46003207-4794E377-46CA-4798-AB54-7541550C67E5 Q46594751-BB083504-1AB3-4C2C-8C79-4A71E1171DF3 Q47252184-5E6DA3B1-7BAD-4883-A689-1AA1D938C253 Q47303510-74C17145-F8E7-46BC-BACA-B79F7CC11436 Q47407413-D23C66C8-95E3-4A83-8DFC-147D4FFF2427 Q55128164-B08FFFB8-2A4A-47AC-B672-5D7FE4B184A7 Q57177981-20082B97-047C-4AF0-8FB0-484C65601EF3

P2860

Predictors of weight loss in adults with topiramate-treated epilepsy.

http://www.wikidata.org/entity/Q44400054

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Predictors of weight loss in adults with topiramate-treated epilepsy.

@en

Predictors of weight loss in adults with topiramate-treated epilepsy.

@nl

type

label

Predictors of weight loss in adults with topiramate-treated epilepsy.

@en

Predictors of weight loss in adults with topiramate-treated epilepsy.

@nl

prefLabel

Predictors of weight loss in adults with topiramate-treated epilepsy.

@en

Predictors of weight loss in adults with topiramate-treated epilepsy.

@nl

P1433

Q44400054-C5427EF8-9CB4-4FAC-9486-4044C35164CD

P1476

Q44400054-21C3F70A-4ACE-4E7B-8976-FAAF5F07D04E

P2093

Q44400054-09F21D42-E938-45D3-9609-9B7EDC6350B4

Q44400054-18A48E5E-9A08-4125-9BCA-D4C67D92D5BE

Q44400054-4F6AEBF3-E82B-452A-8C55-7A006827B439

Q44400054-824A79A7-4698-4A9C-9713-0AEF74667BBF

Q44400054-AA23C945-687E-4729-8D32-26E80FE0B497

P2860

Q44400054-18E99D5F-10E3-4A9C-ACE0-FF8D7A8160A9

Q44400054-3AEC5490-61D5-4F99-BE95-5AE1FB92E920

Q44400054-5F33A882-A4FE-45BA-9D3C-7083F3F5F304

Q44400054-643DD48A-EC93-465D-AD76-AD84956AC4F2

Q44400054-979581DA-7059-4132-BC10-A8D75F33978B

Q44400054-9FB41E80-26A5-4BB0-AB06-D42C1117D8E5

Q44400054-A1BDA720-3CAA-403E-9FC7-785C02C09748

Q44400054-AE13FF5E-0B28-4F29-886B-910122BA42FA

Q44400054-D6B4F5B1-AC53-4FF0-A3FB-C13A1E72E573

Q44400054-FDA2D85E-13CB-4F31-984D-C1FAFF06DC9F

P304

Q44400054-0485DB27-6B30-4DB6-BF03-69573B745098

P31

Q44400054-8CF048A8-7FC9-486C-8F92-48D9F63C49F5

P356

Q44400054-68181F63-473E-449B-9B9B-203B3B67407E

P433

Q44400054-771ACEF9-8879-41E4-87F7-704C01B87361

P478

Q44400054-00569445-1B92-4F60-A140-B5D471CC40C7

P577

Q44400054-27469947-B667-4410-A8EF-DFAAEDBF9060

P5875

Q44400054-AC3C2A95-1185-4CCD-B9A8-90BAB400FF2E

P698

Q44400054-10158B34-7450-4666-BCFA-96F52C2030BD

P356

P1433

P1476

Predictors of weight loss in adults with topiramate-treated epilepsy.

@en

P2093

Anna Stagge

http://www.w3.org/2001/XMLSchema#string

Elinor Ben-Menachem

http://www.w3.org/2001/XMLSchema#string

Else Hellebö Johanson

http://www.w3.org/2001/XMLSchema#string

Mette Axelsen

http://www.w3.org/2001/XMLSchema#string

Ulf Smith

http://www.w3.org/2001/XMLSchema#string

P2860

A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group.

Impact of overweight on the risk of developing common chronic diseases during a 10-year period.

A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group.

Influence of topiramate in the regulation of energy balance.

Effect of topiramate on body weight and body composition of osborne-mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs.

Open-label adjunctive topiramate in the treatment of bipolar disorders.

Weight loss with topiramate.

Topiramate in migraine prevention: a double-blind, placebo-controlled study.

The disease burden associated with overweight and obesity.

Mood stabilization and weight loss with topiramate.

P304

556-562

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/OBY.2003.78

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2003-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10809706

http://www.w3.org/2001/XMLSchema#string

P698

12690085

http://www.w3.org/2001/XMLSchema#string